Skip to main content
BMC Research Notes logoLink to BMC Research Notes
. 2008 Jul 21;1:48. doi: 10.1186/1756-0500-1-48

Radical prostatectomies in Austria, 1997–2004

Gerald Haidinger 1,, Stephan Madersbacher 2, Georg Schatzl 3, Christian Vutuc 1
PMCID: PMC2533339  PMID: 18710501

Abstract

Background

The introduction of PSA testing in Austria led to a steep increase of the incidence of prostate cancer. We want to present the course of the number of newly diagnosed cases of prostate cancer in Austria since 1997, and set these numbers in relation to the total of radical prostatectomies (with resection of lymph nodes) in the same time period. All numbers were retrieved from health statistics of Statistics Austria. The report period of cancer cases and of RPE comprises the years 1997–2004. All calculations were performed for totals as well as for 5-year age groups (40–89 years of age).

Findings

The number of prostate cancer cases rose from 1997 to 2004 by 35%, while the number of RPE rose by 94% in the same time period. The proportion of RPE in relation to new cases rose from 41% in 1997 to 59% in 2004.

Conclusion

A slight decrease of prostate cancer mortality can already be observed in Austria, but the question of over-treatment still awaits analysis.

Findings

Opportunistic Prostate-Specific-Antigen testing (PSA) of healthy men started at the beginning of the 1990s and led to a steep increase of prostate cancer incidence [1-3]. In Austria data on surgical treatment of prostate cancer are available since 1997. The purpose of this paper is to present the correlation between the number of newly detected cases and the number of radical prostatectomies with resection of lymph nodes (RPE) by 5 year age group.

Data on the number of newly detected cases and number of prostatectomies where obtained from Statistics Austria. The data on radical prostatectomies by age group are available since 1997 only. The data set covers the age group 40 to 89 years comprising a population of 1.738,655 men in the year 2000. Since cases are anonymized it is indeterminable whether newly detected cases are operated in the year of diagnosis or in the following year, if ever.

Cases treated by perineal cryosurgery were excluded, due to the small total number (0 to 2 cases per year).

The number of newly detected cases and of RPE (1997 through 2004) as well as the calculated percentage per year by 5 year age group are given in table 1. The absolute number of prostate cancer cases rose from 3999 in 1997 to 5416 in 2004 (+35.4%, all age groups). The absolute number of RPE rose from 1648 in 1997 to 3200 in 2004 (+94.2%, all age groups). The percentage of RPE in relation to the number of newly detected cases rises from 41% in 1997 to 59% in 2004 (all age groups). The increase of this percentage is observed in all age groups younger than 70 years but not in older age groups, the linear trend over time is significant for all age groups and for totals, except for age group 40–44 years.

Table 1.

Number of newly detected cases of prostate cancer in Austria, and number of radical prostatectomies 1997–2004, as well as proportion of RPE/incidence, and P value for linear time trend, totals and 5-year age groups of men aged 40–89.

Age 1997 1998 1999 2000 2001 2002 2003 2004
Nndc RPE Nndc RPE Nndc RPE Nndc RPE Nndc RPE Nndc RPE Nndc RPE Nndc RPE

n n % n n % n n % n n % n n % n n % n n % n n % P-value

40–44 3 4 >100 5 4 80 5 4 80 16 14 87 18 15 83 17 18 >100 22 17 77 25 25 100 0.338
45–49 26 21 81 40 37 92 44 35 80 74 71 96 85 81 95 95 87 92 125 123 98 109 118 >100 < 0.001
50–54 127 99 78 149 118 79 166 157 95 199 171 86 256 240 94 266 259 97 267 279 >100 254 258 >100 < 0.001
55–59 371 300 61 440 382 87 496 433 87 522 482 92 541 518 96 559 492 88 597 552 92 585 612 >100 < 0.001
60–64 490 369 75 528 359 68 589 454 77 784 688 88 907 798 88 995 884 89 1158 1067 92 1105 980 89 < 0.001
65–69 841 515 61 880 568 65 924 560 61 938 666 71 962 685 71 910 651 72 1065 842 79 1011 789 78 < 0.001
70–74 837 299 36 873 288 33 976 288 30 1042 355 34 1035 390 38 998 370 37 1074 500 47 1001 377 38 < 0.001
75–79 554 34 6 655 31 5 737 38 5 698 40 6 674 42 6 644 26 4 732 119 16 718 36 5 < 0.001
80–84 383 4 1 300 2 <1 316 0 0 333 1 <1 328 2 <1 339 0 0 403 38 9 367 2 <1 < 0.001
85–89 367 0 0 348 0 0 340 0 0 317 1 <1 322 1 <1 258 0 0 284 15 5 325 1 <1 < 0.001

Total 3999 1648 41 4218 1826 43 4593 1969 43 4923 2489 51 5128 2774 54 5081 2791 55 5727 3167 55 5416 3200 59 < 0.001

Nndc ... Number of newly detected cases.

RPE ... Radical Prostatectomy (with resection of lymph nodes).

P-value ... P value for linear time trend.

The increase of the incidence of prostate cancer is well documented for Austria [1,2], however the absolute numbers are for the first time set in relation to the number of RPE nationwide. Within 8 years, the total number of RPE increased by 94.2%, thus nearly doubled, with the increase mainly occurring in the age group 55–69 years. Starting at age 70 years the percentage of RPE remains more or less stable on a substantially lower level.

The number of RPE we used in our calculations represents the official hospital discharge statistics of Austria comprising of the collected data of all hospitals (including private hospitals), but excludes a very small number of self-pay patients. Thus our results negligibly may underestimate the relation of RPE to the number of newly detected cases. A further limitation of our analyses is caused by legal constrains: due to data protection laws we are limited to the use of depersonalized data.

The increase of RPE in Austria can be explained by at least three factors: a) operation technique meliorated significantly, now is a standard procedure, perioperative mortality is low and the risk of postoperative morbidity such as incontinence and erectile dysfunction decreased in Austria [4,5], consequently acceptance of RPE in patients increased. b) By the introduction of PSA testing the target group of prostate cancer screening shifted towards younger age groups, meaning that carcinoma more frequently is sought in younger men [3]. c) Because of the slow progression of most cases, RPE only makes sense when health status permits RPE and patients have a life expectancy of at least 10 years [6].

The high percentage of RPE in men younger than 70 years surely also is influenced by the fact that counselling (towards RPE or radiation therapy) in Austria is performed by urologists. In this context, it is worth mentioning, that the primary intention of this manuscript is to provide the data which can serve as a basis for a constructive discussion about counselling and the provision of the most adequate therapeutic regimes.

The reason for the more or less stable percentage in men aged 70 years or older may lie in the fact that therapy of prostate cancer in these patients more often relies on watchful waiting, active surveillance, external beam radiation, brachytherapy or hormonal treatment. Detailed data for these therapies are not available.

In conclusion, currently 59% of prostate cancer cases detected are treated by RPE, a percentage steadily rising from 1997 on. On one hand, the dramatic increase of RPE already leads to a slight reduction of prostate cancer mortality in Austria [3,7], on the other hand the question of over-testing and over-treatment, and added morbidity remains unanswered and analyses are still pending for Austria.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

GH and CV planned the study and drafted the manuscript. CV obtained the data, GH and CV performed the statistical analysis. SM and GS contributed in preparing the manuscript. All authors read and approved the final manuscript.

Contributor Information

Gerald Haidinger, Email: gerald.haidinger@meduniwien.ac.at.

Stephan Madersbacher, Email: madersbacher@hotmail.com.

Georg Schatzl, Email: georg.schatzl@meduniwien.ac.at.

Christian Vutuc, Email: christian.vutuc@meduniwien.ac.at.

References

  1. Vutuc C, Waldhoer T, Madersbacher S, Micksche M, Haidinger G. Prostate cancer in Austria: impact of prostate-specific antigen test on incidence and mortality. Eur J Cancer Prev. 2001;10:425–428. doi: 10.1097/00008469-200110000-00006. [DOI] [PubMed] [Google Scholar]
  2. Vutuc C, Schernhammer ES, Haidinger G, Waldhoer T. Prostate cancer and prostate specific antigen (PSA) screening in Austria. Wien Klin Wochenschr. 2005;117:457–61. doi: 10.1007/s00508-005-0395-y. [DOI] [PubMed] [Google Scholar]
  3. Vutuc C, Waldhoer T, Sevelda P, Micksche M, Haidinger G. Self-reported prostate cancer screening in Austria. J Med Screening. 2006;13:148–151. doi: 10.1258/096914106778440680. [DOI] [PubMed] [Google Scholar]
  4. Ponholzer A, Brössner C, Struhal G, Marszalek M, Madersbacher S. Lower urinary tract symptoms, urinary incontinence, sexual function and quality of life after radical prostatectomy and external beam radiation therapy: real life experience in Austria. World J Urol. 2006;24:325–330. doi: 10.1007/s00345-006-0075-1. [DOI] [PubMed] [Google Scholar]
  5. Badereddin A-A, Marszalek M, Brössner C, Ponholzer A, Wehrberger C, Willinger M, Madersbacher S. Radical prostatectomy in Austria: a nationwide analysis of 16,524 cases. Eur Urol. 2007;51:684–689. doi: 10.1016/j.eururo.2006.06.022. [DOI] [PubMed] [Google Scholar]
  6. Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Anderson S-O, Bratell S, Spångberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO, Norlén BJ, Johansson JE, Scandinavian Prostate Cancer Group Study No. 4 Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977–1984. doi: 10.1056/NEJMoa043739. [DOI] [PubMed] [Google Scholar]
  7. Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schonitzer D, Severi G, Robertson C, Boyle P, Tyrol Prostate Cancer Screening Group Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology. 2001;58:417–24. doi: 10.1016/S0090-4295(01)01264-X. [DOI] [PubMed] [Google Scholar]

Articles from BMC Research Notes are provided here courtesy of BMC

RESOURCES